Skip to main content
TipRanks
Go Ultimate75% OFF

Abivax SA (ABVX) AI Stock Analysis

45 Followers
FR:ABVX

Abivax SA

(Paris:ABVX)

Select Model
Rating:44Neutral
Price Target:EUR 79.00â–¼(-0.13% Downside)
Action:reiterated
Date:09/25/26

The score is primarily held back by weak financial performance—ongoing large losses, unstable revenue (including a 2025 drop to zero), and persistent negative free cash flow—despite an improved 2025 balance sheet with low leverage. Technicals add further pressure due to a broad downtrend and negative momentum indicators. Valuation provides limited support because earnings are negative and there is no dividend yield.

Positive Factors
Improved Balance SheetThe materially lower leverage and stronger equity base improve financial flexibility compared with prior years. This can help Abivax sustain research and development and manage near-term obligations, although the benefit is mainly a stronger funding position rather than internally generated profitability.
Negative Factors
Persistent Cash BurnPersistent negative operating and free cash flow means the company is not self-funding its research and operations. The roughly -162M 2025 free cash flow highlights a continuing need to finance development externally, which can constrain strategic flexibility and increase funding dependence.

Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)

-40%-20%0%20%40%FR:ABVX-19.86%EWQ+2.16%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 6.93B
Dividend Yield
―
Average Volume (3M)
130.18K
Price to Earnings (P/E)
-16.8
Beta (1Y)
1.19
Revenue Growth
―
EPS Growth
―
Country
France
Employees
98
Sector
General
Sector Strength
55
Industry
Biotechnology

Abivax SA Business Overview & Revenue Model

Company Description

Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ABX...

How the Company Makes Money

Abivax SA does not have a disclosed commercial product revenue stream and, as a clinical-stage biopharmaceutical company, its operations are primarily funded through external financing rather than sales. The company’s cash inflows typically come from...

Abivax SA Financial Statement Overview

Summary

Financial performance is constrained by large and widening net/operating losses and consistently negative operating and free cash flow (high cash burn). The main offset is an improved 2025 balance sheet with low leverage and higher equity, which supports liquidity/runway, but the business remains reliant on external funding given minimal/unstable revenue (including a drop to zero in 2025).

Income Statement

12Very Negative

Balance Sheet

55Neutral

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Dec 2022Dec 2021
Income Statement
Total Revenue-2.02M010.79M4.62M4.58M37.00K
Gross Profit-3.09M-1.07M10.79M4.49M4.51M-119.00K
EBITDA-278.97M-249.55M-167.68M-133.21M-53.31M-42.20M
Net Income-352.75M-336.10M-176.24M-147.74M-60.74M-42.45M
Balance Sheet
Total Assets462.21M584.34M205.23M327.06M73.35M110.36M
Cash, Cash Equivalents and Short-Term Investments410.68M530.38M144.22M260.99M26.95M60.70M
Total Debt1.21M32.09M97.36M55.46M39.16M53.45M
Total Liabilities95.94M129.14M164.64M131.05M71.47M81.59M
Stockholders Equity366.27M455.20M40.58M196.01M7.19M25.93M
Cash Flow
Free Cash Flow-147.65M-162.23M-154.72M-97.39M-69.55M-47.30M
Operating Cash Flow-147.46M-162.09M-154.07M-97.13M-65.58M-45.66M
Investing Cash Flow4.25M-13.72M15.76M-8.10M-3.73M-1.46M
Financing Cash Flow564.11M553.80M28.21M335.29M32.21M82.68M

Abivax SA Technical Analysis

Technical Analysis SentimentNegative
Last Price79.10

Price Trends

50DMA84.13Negative
100DMA97.20Negative
200DMA97.99Negative

Market Momentum

MACD-0.93Negative
RSI46.18Neutral
STOCH76.11Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Negative. The current price of 79.10 is below the 20-day moving average (MA) of 79.86, below the 50-day MA of 84.13, and below the 200-day MA of 97.99, indicating a bearish trend. The MACD of -0.93 indicates Negative momentum. The RSI at 46.18 is Neutral, neither overbought nor oversold. The STOCH value of 76.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ABVX.

Abivax SA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

FR:ABVX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
FR:VLAFR:VLA51NeutralEUR 488.58M-2.85-152.15%―-27.19%-117.39%
FR:IPHFR:IPH48NeutralEUR 134.04M-2.35152.56%―-29.48%7.91%
FR:ALCLSFR:ALCLS46NeutralEUR 76.38M-1.78-94.14%―-5.98%-8.67%
FR:TNGFR:TNG45NeutralEUR 200.64M-4.31-29.36%―189.81%38.50%
FR:DBVFR:DBV44NeutralEUR 618.29M-3.62-121.83%――45.11%
FR:ABVXFR:ABVX44NeutralEUR 6.93B-16.79-85.88%―――

* General Sector Average

Performance Comparison

-50%0%50%FR:ABVXFR:IPHFR:DBVFR:TNGFR:VLAFR:ALCLSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ABVX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ABVXAbivax SA79.10-18.10-18.62%
FR:IPHInnate Pharma S.A.1.20-0.37-23.37%
FR:DBVDbv Technologies SA (UK)1.97-0.43-17.87%
FR:TNGTransgene SA0.72-0.58-44.75%
FR:VLAValneva (0OB3)2.57-1.26-32.88%
FR:ALCLSCellectis SA1.06-2.64-71.42%

Abivax SA Corporate Events

Abivax to Present at Five Investor Conferences This Fall

Nov 2, 2026

Abivax announced plans to participate in five investor and healthcare conferences from November 9 to December 3, 2026, with events scheduled in Boston, London, Frankfurt, Miami and New York. Company representatives will take part in fireside chats an...

Abivax Updates Share Capital and Voting Rights Structure as of September 30, 2026

Oct 23, 2026

Abivax disclosed updated capital and voting rights data as of September 30, 2026, reporting a share capital of €875,481 represented by 87,541,485 shares and 88,796,742 theoretical and exercisable voting rights. The publication complies with French co...

Abivax to Showcase Extensive Obefazimod Data at UEG Week 2026

Sep 30, 2026

Abivax SA will showcase seven scientific abstracts on its lead drug candidate obefazimod at United European Gastroenterology Week 2026 in Barcelona, highlighting extensive clinical and preclinical data in ulcerative colitis and related inflammatory c...

Abivax Updates Share Capital and Voting Rights Structure as of August 31, 2026

Sep 25, 2026

Abivax reported that, as of August 31, 2026, its share capital consists of 87,271,525 shares, corresponding to 88,526,782 theoretical and exercisable voting rights under French market regulations. The disclosure, made in line with requirements of the...

Abivax bolsters leadership and balance sheet as obefazimod nears commercialization

Sep 21, 2026

Abivax has overhauled its leadership team as it prepares for potential commercialization of obefazimod, appointing Chris Rabbat as Chief Medical Officer and Tim Kelly as Chief Technical Officer. These changes are designed to bolster medical, CMC, qua...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 25, 2026